HCA Healthcare, Inc. (HCA) stock intrinsic value fair value estimate & owner earnings analysis

HCA Healthcare is the largest investor-owned hospital operator in the United States: about 190 hospitals and roughly 2,500 outpatient sites (surgery centres, freestanding emergency rooms, urgent care, physician clinics) clustered in fast-growing markets in Texas, Florida, Tennessee and the rest of the South and West, plus a small private hospital business in London. Revenue was $75.6 billion in 2025, up from $41.5 billion in 2016. The business is a toll on population growth and ageing in its markets, with dense local networks that insurers struggle to leave out. What the owners earned. We measure owner earnings as operating cash flow, with working-capital swings removed, less stock compensation and the capital spending needed to keep existing facilities competitive. HCA spends about 6.9% of revenue on capital projects on average; we treat the part of each year's spending that matches revenue growth as expansion rather than upkeep. On that basis owner earnings rose from $2.7 billion in 2016 to $5.2 billion in 2023, $5.8 billion in 2024 and $7.2 billion in 2025 ($30.14 per diluted share). Two adjustments matter for valuing the shares. First, about $1.0 billion a year of that cash is earned by minority partners in jointly owned hospitals (often physician groups or non-profit systems) and is paid out to them, so it is excluded. Second, because the company is heavily borrowed, we value the business before interest (cash interest was $2.2 billion in 2025) and then subtract the debt once. That stream - cash available to HCA's lenders and shareholders together - was $6.7 billion in 2021, $5.5 billion in 2022 (a year of contract-nurse cost inflation), $6.3 billion in 2023, $6.8 billion in 2024 and $8.4 billion in 2025. We anchor on $6.7 billion, the median of 2021-2025, deliberately below 2025. The 2025 figure was lifted by $6.2 billion of Medicaid supplemental and state-directed payments (up from $4.4 billion in 2023) and by subsidised marketplace insurance enrolment; both are now being reversed by law. The enhanced marketplace premium tax credits expired at the end of 2025, and the 2025 federal budget law caps new provider taxes from October 2026 and cuts grandfathered state-directed payments by 10 percentage points a year from 2028 until they reach the new limits. The company itself says these programmes will decline in 2026. Years before 2021 describe a smaller business (diluted shares were 396 million in 2016 against 227 million today) and 2020 was distorted by pandemic relief grants. Growth path. Cash available before interest grew 24% in 2025; we assume only 1% in 2026 and 2027 and 1% a year from 2028 through 2032 while state-directed payments step down, then 4% a year through 2035. The only growth we credit is HCA's long-demonstrated process of adding beds and outpatient sites in its existing markets from its own cash: it has $7.1 billion of projects already under construction and has grown revenue about 6-7% a year for a decade through COVID and the 2022 labour squeeze. We do not credit further share-count reduction, market-share gains or margin expansion. After 2035 we credit 2% a year to 2055, reflecting the continued ageing and growth of its Sunbelt markets and the replacement-cost moat of its hospital networks, and then hold earnings flat. Debt. Total borrowings were $48.0 billion at 31 March 2026 (including $8.5 billion due within a year, largely commercial paper backed by its credit facility) against $0.9 billion of cash, so net debt is about $47.1 billion, or roughly $208 per share. The debt is mostly fixed-rate senior notes at around 5% with maturities spread from 2026 to 2095 (about $2.5-4.0 billion a year in 2027-2030); its fair value is close to par, so we make no cost-of-debt adjustment. The minority partners' share is already excluded from the cash stream, so it is not subtracted again. Cases. Base: the path above. The business is worth about $151 billion; less $47 billion of net debt leaves $104 billion, or about $457 per share. Bear: a hospital recession of the 2008-2010 kind - elevated unemployment pushes patients from employer insurance to Medicaid and uninsured status while labour costs stay sticky - layered on top of the policy changes already enacted. Cash before interest falls to $6.4 billion in 2026, $5.6 billion in 2027 and $5.2 billion in 2028, then declines 3% a year through 2033 as state-directed payments are phased down to the new caps, bottoming near $4.5 billion before resuming 1-2% growth. Even at the trough, cash covers the roughly $2.3 billion interest bill about twice, so the debt can be carried and refinanced. The business is worth about $87 billion; less $47 billion of debt leaves $39 billion, or about $174 per share. Bull: the supplemental-payment step-down is modest, as HCA's states win approvals for grandfathered programmes they have already filed, and the bed and outpatient build-out continues at 5% a year (below the decade's revenue growth) to 2035, then 3%. The business is worth about $230 billion, less $47 billion of debt, about $807 per share. How sure are we, and what could go wrong. We are fairly confident in the earnings level: hospital demand in HCA's markets is steady, and the anchor already sits well below 2025. The biggest uncertainty is government: Medicare, Medicaid and the supplemental programmes make up a large share of revenue and are set by legislators and regulators, not by HCA. The worst plausible outcome no case fully models is a combination of deep federal Medicaid funding cuts and a recession at the same time; with net debt about seven times annual cash before interest, a 20% fall in that cash removes roughly 40% of what is left for shareholders. The structure would survive it - hard assets, no large single customer, staggered long-dated debt, and an investment-grade-style maturity profile - but the shares would be worth something near the bear case. If we are wrong about the supplemental-payment phase-down (it could be harsher), about labour costs (2022 showed they can rise fast) and about recession timing together, value lands in the high $100s to low $200s. Margin-of-safety price. During the holding period, the business pays a dividend of about $3 per share and retires shares with its free cash. Measured against $200 a share, the owners' portion of normal earnings after interest (about $4.5 billion, or roughly $20 per share) is a 10% yield, and that price sits only modestly above what the shares appear to be worth after a full recession plus the enacted policy cuts. From there, simply reaching the middle of our range over five to seven years, with the payout and buybacks along the way, implies about a 20% annual return, while the bear case implies roughly breaking even. Above $200 the leverage means a recession scenario could leave the return well short of the target for years, so the margin-of-safety price is $200. Change since our previous estimate: our previous figures were prepared on a different basis and are not comparable. On the business itself, the main development is that the policy headwinds flagged earlier are now enacted law with dated phase-downs, which we have built into all three cases.